Group 1 - A class action lawsuit has been filed against Sable Offshore Corp. by Berger Montague PC on behalf of investors who acquired Sable's publicly traded securities between May 19, 2025, and June 3, 2025 [1][2] - The lawsuit alleges that Sable made materially false and misleading statements regarding the status of its oil production, specifically claiming that production had restarted off the coast of California when it had not [3] - These misrepresentations are said to have artificially inflated Sable's stock price, leading to investor harm when the truth was revealed [3] Group 2 - Investors who purchased Sable securities during the class period have until September 26, 2025, to seek appointment as lead plaintiff representative [2] - Berger Montague has a long history in securities class action litigation, having represented individual and institutional investors for over five decades [4]

Core Viewpoint - National plaintiffs' law firm Berger Montague PC is investigating securities fraud claims against Spectrum Pharmaceuticals, Inc. on behalf of investors who acquired shares during the specified class period [1][2] Group 1: Legal Investigation - The investigation focuses on claims that Spectrum made false or misleading statements regarding its Pinnacle Study, a clinical trial for the drug poziotinib aimed at treating certain lung cancer patients [3] - Investors who purchased Spectrum securities between March 17, 2022, and September 22, 2022, are eligible to seek appointment as lead plaintiff representative by the deadline of September 24, 2025 [2] Group 2: Company Background - Spectrum Pharmaceuticals is a biopharmaceutical company that specializes in oncology treatments [2] - Following a merger with Assertio Holdings, Inc., Spectrum shares were delisted [3]

Core Viewpoint - A class action lawsuit has been filed against Novo Nordisk A/S by Berger Montague PC on behalf of investors who acquired Novo's publicly traded securities during the specified class period from May 7, 2025, to July 28, 2025 [1][2] Company Summary - Novo Nordisk A/S is a global pharmaceutical company headquartered in Denmark [3] - The lawsuit alleges that Novo understated the impact of the personalization exception to the compounded GLP-1 exclusion, which has allowed continued use of compounded alternatives to its products [3] - The company is accused of overstating the likelihood that patients using less expensive compounded drugs would switch to its branded products, leading to an overestimation of its long-term growth potential [3] Financial Performance - On July 29, 2025, Novo announced a reduction in its sales and profit outlook for fiscal 2025, citing slower-than-expected growth for its products Wegovy® and Ozempic® [4] - The guidance revision was attributed to ongoing competition from compounded GLP-1 products [4] - Following this announcement, Novo's stock price fell from $69.00 per share on July 28, 2025, to $53.94 per share on July 29, representing a decline of approximately 21.83% in one day [4]

PHILADELPHIA, July 31, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC is investigating potential claims against Fiserv, Inc. (NYSE: FI) ("Fiserv" or the "Company") related to alleged securities law violations. This investigation follows the filing of a securities class action lawsuit against Fiserv and certain of its senior executives on behalf of investors who purchased the Company's securities between July 24, 2024 and July 22, 2025 (the "Class Period"). Investor Deadline: Investors ...

Core Viewpoint - Berger Montague PC is investigating claims against Sable Offshore Corp. following a class action lawsuit alleging misrepresentation of oil production status [1][3]. Group 1: Company Overview - Sable Offshore Corp. is an offshore oil and gas operations company based in Houston, Texas [1]. - The company is publicly traded on the New York Stock Exchange under the ticker symbol SOC [1]. Group 2: Legal Proceedings - A class action lawsuit has been filed against Sable, claiming that the company falsely stated that oil production off California's coast had resumed when it had not [3]. - Investors who purchased Sable securities between May 19, 2025, and June 3, 2025, are eligible to seek appointment as lead plaintiff representative by September 26, 2025 [2]. Group 3: Impact on Investors - The revelation of the true state of Sable's operations led to a decline in share prices, resulting in losses for investors [3].

Core Viewpoint - Rocket Pharmaceuticals is facing a class action lawsuit for allegedly concealing safety concerns related to its RP-A501 trial, which has resulted in significant investor losses [1][2]. Company Overview - Rocket Pharmaceuticals is based in Cranbury, New Jersey, and focuses on research and clinical programs in genetic medicine [2]. Legal Issues - The lawsuit claims that Rocket Pharmaceuticals failed to disclose the introduction of a new immunomodulatory agent in the RP-A501 protocol before a patient experienced a fatal adverse event [2]. - Following the announcement of an FDA clinical hold, Rocket Pharmaceuticals' stock price declined nearly 37% over two trading days [2]. Class Action Details - Individuals who purchased Rocket Pharmaceuticals securities from September 17, 2024, to May 26, 2025, may be eligible to join the class action [3]. - The deadline to file for lead plaintiff status is August 11, 2025 [3].

Core Viewpoint - A class action lawsuit has been filed against Sable Offshore Corp. for allegedly making false statements regarding its oil production status, which misled investors and inflated stock prices [1][3]. Company Overview - Sable Offshore Corp. is headquartered in Houston and operates in offshore oil and gas [3]. Legal Action Details - The lawsuit is initiated by Berger Montague PC on behalf of investors who acquired Sable securities between May 19, 2025, and June 3, 2025, including during the Company's secondary public offering in May 2025 [1][2]. - Investors are encouraged to seek appointment as lead plaintiff representatives by the deadline of September 26, 2025 [2]. Allegations - The complaint alleges that Sable misrepresented the status of its oil production, claiming it had restarted operations off the coast of California when it had not, leading to an artificial inflation of the stock price [3].

Core Viewpoint - Berger Montague PC is investigating potential claims against Fiserv, Inc. related to alleged securities law violations following a class action lawsuit filed against the company and its senior executives [1][3]. Group 1: Legal Investigation - The investigation is prompted by a securities class action lawsuit on behalf of investors who purchased Fiserv securities between July 24, 2024, and July 22, 2025 [1][2]. - Investors have until September 22, 2025, to seek appointment as lead plaintiff representative of the class [2][4]. Group 2: Allegations Against Fiserv - The lawsuit alleges that Fiserv and certain executives overstated the company's growth by failing to disclose that its new payment platform, Clover, was experiencing increased revenue growth and gross payment volumes due to the forced transition of merchants from the legacy Payeezy platform [3].

Core Viewpoint - Berger Montague PC is investigating potential securities law violations involving RxSight, Inc. following a class action lawsuit filed on behalf of investors who acquired RxSight securities during the specified class period [1][2]. Company Overview - RxSight, Inc. is a medical technology company based in Aliso Viejo, CA, specializing in light adjustable intraocular lenses (LAL) used in cataract surgery, with its system involving the Light Delivery Device (LDD) [2]. Legal Allegations - The lawsuit alleges that RxSight's management failed to disclose significant issues, including: 1. Adoption challenges and structural issues leading to declines in sales and utilization [3]. 2. Overstated demand for RxSight's products [3]. 3. Unlikelihood of meeting previously issued financial guidance for fiscal year 2025 [3]. Financial Impact - On July 8, 2025, RxSight reported significant declines in LDD sales, LAL utilization, and overall revenue for Q2 2025, subsequently lowering its full-year 2025 revenue guidance. CEO Ronald Kurtz attributed the sales stall to adoption challenges over recent quarters [4]. - Following this announcement, RxSight shares fell by $4.84, or 37%, closing at $7.95 per share on July 9, 2025 [4].

Core Viewpoint - Rocket Pharmaceuticals is facing a securities class action lawsuit alleging misleading safety disclosures related to its RP-A501 gene therapy program, which has resulted in significant stock price decline following a serious adverse event [1][3]. Company Overview - Rocket Pharmaceuticals, based in Cranbury, New Jersey, specializes in developing gene therapies for rare diseases [2]. Legal Allegations - The lawsuit claims that Rocket Pharmaceuticals did not inform investors about a significant protocol change involving a new immunomodulatory agent before a serious adverse event occurred, leading to a clinical hold by the FDA [3]. - Following the disclosure of a patient death during the trial, Rocket Pharmaceuticals' stock plummeted nearly 37%, dropping from $6.27 on May 23, 2025, to $2.33 on May 27, 2025 [3]. Investor Information - Investors who purchased Rocket Pharmaceuticals securities between February 27, 2025, and May 26, 2025, may be eligible for recovery, with a lead plaintiff application deadline set for August 11, 2025 [4].